Natco Pharma plans to launch the generic version of
Sovaldi, the blockbuster drug used to treat chronic Hepatitis C in India
soon. Sovaldi is made by U.S. pharma major Gilead Sciences, and Natco
recently entered into a non-exclusive licensing agreement with Gilead to
make and sell generic versions of Sovaldi in 91 developing countries.
company, on Monday, launched the generic version of Sovaldi in Nepal
under the brand Hepcinat. The product is priced at Rs.19,900 (US $316.68) per bottle
of 28 tablets in Nepal, and covers the treatment duration of three
months for a patient.
“We will be launching the drug
in the next few weeks in India, and are awaiting approval from the Drugs
Controller General of India (DCGI),” M. Adinarayana, Vice-President,
Legal & Corporate Affairs, Natco Pharma, told this correspondent.
Labels: generic Sovaldi, HEPCINAT, India